Company: BIAF
Filing Date: 2025-04-22
Form Type: 424B3
Source: 0001641172-25-005598
Chunk: 46

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-04-22
Form: 424B3
Chunk 46
---
 and therefore our, revenue and business.

Risks Related to Intellectual Property Rights

Intellectual property rights do not necessarily address all potential threats to our competitive advantage.

The degree of future protection afforded by our intellectual
property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit
us to maintain our competitive advantage. For example:

| ● | others may be able to make diagnostic tests and therapeutic product candidates that are the same as or similar to ours but that are not covered by the claims of the patents that we own or have exclusively licensed;                                                                                                                                                                            |
| ● | we or our licensors or future collaborators might not have been the first to make the inventions covered by the issued patent or pending patent application that we own or have exclusively licensed;                                                                                                                                                                                             |
| ● | we or our licensors or future collaborators might not have been the first to file patent applications covering certain of our inventions;                                                                                                                                                                                                                                                         |
| ● | others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;                                                                                                                                                                                                                                    |
| ● | it is possible that noncompliance with the U.S. Patent and Trademark Office (“USPTO”) and foreign governmental patent agencies requirement for a number of procedural, documentary, fee payment, and other provisions during the patent process can result in abandonment or lapse of a patent or patent application, and partial or complete loss of patent rights in the relevant jurisdiction; |
| ● | it is possible that our pending patent applications will not lead to issued patents;                                                                                                                                                                                                                                                                                                              |

| ● | issued patents that we own or have exclusively licensed may be revoked, modified, or held invalid or unenforceable, as a result of legal challenges by our competitors;                                                                                                                                                            |
| ● | our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive tests and products for sale in our major commercial markets;                                                                    |
| ● | we may not develop additional proprietary technologies that are patentable;                                                                                                                                                                                                                                                        |
| ● | we cannot predict the scope of protection of any patent issuing based on our patent applications, including whether the patent applications that we own or in-license will result in issued patents with claims that are directed to our diagnostic tests and product candidates or uses thereof in the U.S. or foreign countries; |
| ● | there may be significant pressure on the U.S. government and international governmental bodies to limit the scope of patent protection both inside and outside the U.S